Agencies, 08 January: Drug Controller General of India (DCGI) para Emergency Use Authorisation nemite mana COVID-19 vaccine Covaxin, Bharat Biotech para virus nemite notun intranasal antidote laga Phase-1 clinical trials toh etu sal February-March samai te suru koribo koise.
Covaxin opor te, Bharat Biotech toh tusara vaccine bonabole nemite actively kaam kori ase. Etu nemite St Louis te Washington University School of Medicine logote melikena. Etu toh novel “chimp-adenovirus” (Chimpanzee adenovirus), COVID-19 nemite tranasal dawai nemite.
City-based vaccine maker para email jawab te koise, “BBV154 (intranasal COVID-19 vaccine), preclinical testing toh toxicology, immunogenicity aro challenge studies nemite kothom korise. Etu studies toh USA aro India te loise. Phase I human clinical trials toh Feb-March 2021 samai te suru koribo.
Bharat Biotech para be Phase I human clinical trials toh India te lobo koise. Phase-1 trials toh Saint Louis University’s Vaccine arot Treatment Evaluation Unit te lobo aro Bharat Biotech toh USA, Japan aro Europe ke charikena sob markets ke debole nemite rights paise koise.
Add Comment